Middle-East and Africa Continuous Glucose Monitoring Market is expected to register CAGR of more than 19% during the forecast period. Countries in Middle-East and Africa are suffering from the burden of high diabetes expenditure. According to IDF, the overall diabetes expenditure in Middle-East and Africa, among the population aged between 18 and 99 years, was USD 24.9 billion in 2019 and is expected to increase to USD 38.6 billion by 2045. Every 1 in 11 adults has diabetes in the MENA region, according to IDF. The organization also stated that diabetes caused 418,900 deaths in 2019, in the region. For patients relying on insulin pumps or multiple daily injections (MDI) therapy, CGM proves to be an instrumental tool, which helps in the improvement of glycemic balance without aggregating the danger for severe hypoglycemia. As studied in several clinical trials, diabetic patients with T1DM have been shown to have better glycemic control, as compared to a glucometer. The current, approved CGM products administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in interstitial fluid.
Key Market Trends
Rising Prevalence of Diabetes in Middle-East and Africa Region is Driving the Market Growth
It is estimated that the number of people with diabetes in the Middle-East and Africa region will increase by 38.8% by 2030 and by 96.5% by 2045. Although 55.3% of all adults in the region live in urban areas, 60.6% of adults with diabetes live in urban settings. The majority (87.2%) of adults with diabetes in the region live in low- or middle-income countries. Diabetes and its complications were responsible for an estimated 418,900 deaths in adults aged 20-79 years in 2019 (16.2% of all-cause mortality), with the highest percentage (22.4%) in the age group 30-39 years. About 53.3% of all deaths from diabetes in the Middle-East and Africa occurred in people under 60 years. There is higher mortality due to diabetes in women than men, with 248,300 and 170,600 estimated deaths respectively. In Saudi Arabia, close to 10% of people suffer from diabetes, in which the type-2 diabetic population accounts for 98%. Self Monitoring Blood Glucose is mostly used by the type-1 diabetic population, but in the recent days type-2 population also started using it and the usage is expected to continue to increase in the future.
Saudi Arabia is Expected to Maintain Dominance in the Market
The CGM market in Saudi Arabia reached USD 22 million in 2019 and held a major share of about 53% in the Middle-East and Africa CGM market. The market for CGM in the Middle-East and Africa region is estimated to reach USD 120 million by the end of the forecast period. In Saudi Arabia type-2 diabetes in children and adolescents is increasing. In 2019 alone more than 2,000 children were diagnosed as type-1 diabetes. Many children and adolescents with type-2 diabetes risk developing complications in early adulthood, which places a significant impact on the individual, the family, and society. With increasing levels of obesity and physical inactivity among children and adolescents in Saudi Arabia, type-2 diabetes in childhood and adolescence has the potential to become a health issue leading to serious adverse health outcomes. Iran is anticipated to be the fastest-growing market with a CAGR of about 22% during the forecast period. It is imperative that the CGM devices are used alongside insulin pumps, and as the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the demand for CGM will also increase in the coming years.
Competitive Landscape
The market is highly consolidated in the Middle-East and Africa region. Dexcom, Medtronic, and Abbott held more than 60% of the market share, in 2019. A major share of the market is held by CGM manufacturers that are concomitant with strategy-based M&A operations, and are constantly entering new markets to generate new revenue streams and boost the existing ones. Mergers and acquisitions that took place between the players, in the recent past, has helped the companies strengthen their market presence.
Reasons to Purchase this report:
Key Market Trends
Rising Prevalence of Diabetes in Middle-East and Africa Region is Driving the Market Growth
It is estimated that the number of people with diabetes in the Middle-East and Africa region will increase by 38.8% by 2030 and by 96.5% by 2045. Although 55.3% of all adults in the region live in urban areas, 60.6% of adults with diabetes live in urban settings. The majority (87.2%) of adults with diabetes in the region live in low- or middle-income countries. Diabetes and its complications were responsible for an estimated 418,900 deaths in adults aged 20-79 years in 2019 (16.2% of all-cause mortality), with the highest percentage (22.4%) in the age group 30-39 years. About 53.3% of all deaths from diabetes in the Middle-East and Africa occurred in people under 60 years. There is higher mortality due to diabetes in women than men, with 248,300 and 170,600 estimated deaths respectively. In Saudi Arabia, close to 10% of people suffer from diabetes, in which the type-2 diabetic population accounts for 98%. Self Monitoring Blood Glucose is mostly used by the type-1 diabetic population, but in the recent days type-2 population also started using it and the usage is expected to continue to increase in the future.
Saudi Arabia is Expected to Maintain Dominance in the Market
The CGM market in Saudi Arabia reached USD 22 million in 2019 and held a major share of about 53% in the Middle-East and Africa CGM market. The market for CGM in the Middle-East and Africa region is estimated to reach USD 120 million by the end of the forecast period. In Saudi Arabia type-2 diabetes in children and adolescents is increasing. In 2019 alone more than 2,000 children were diagnosed as type-1 diabetes. Many children and adolescents with type-2 diabetes risk developing complications in early adulthood, which places a significant impact on the individual, the family, and society. With increasing levels of obesity and physical inactivity among children and adolescents in Saudi Arabia, type-2 diabetes in childhood and adolescence has the potential to become a health issue leading to serious adverse health outcomes. Iran is anticipated to be the fastest-growing market with a CAGR of about 22% during the forecast period. It is imperative that the CGM devices are used alongside insulin pumps, and as the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the demand for CGM will also increase in the coming years.
Competitive Landscape
The market is highly consolidated in the Middle-East and Africa region. Dexcom, Medtronic, and Abbott held more than 60% of the market share, in 2019. A major share of the market is held by CGM manufacturers that are concomitant with strategy-based M&A operations, and are constantly entering new markets to generate new revenue streams and boost the existing ones. Mergers and acquisitions that took place between the players, in the recent past, has helped the companies strengthen their market presence.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Dexcom
- Medtronics
- Senseonics
Methodology
LOADING...